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distal to the aortic crossclamp, that is, after ischemia. The dif-
ferent results are probably related to how fast the memantine
can cross the blood-brain barrier. Had the intra-arterial infu-
sion been performed over a 30-minute period before aortic
crossclamping, which of course is impractical, the results
might have been different. We have found that a 20- to 30-
minute period is usually necessary for effects of pharmaco-
logic agents (including those of adenosine and adenosine
triphosphate) to significantly appear in the brain interstitial
fluid after intravenous administration (bolus or infusion).
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Reply to the Editor:
My colleagues and I thank Miyamoto and Miyamoto for
their interest and comments on our recent article regarding
the N-methyl-D-aspartate (NMDA) blocker memantine.1
As we are aware of the protective effect of hypothermia on
the release of excitatory amino acids, we have tried to keep the
rectal temperature in a normothermic range assuming that the
rectal temperature will reflect more accurate spinal cord tem-
perature than esophageal temperature. However, we will addi-
tionally monitor esophageal temperature in future experiments.
With respect to our anesthesia protocol, a comparable
experiment investigating the influence of anesthetics on neu-
rologic recovery showed that ketamine treatment reduced
acute paraplegia but increased delayed paraplegia.2 In our
study, the control group did not show a protective effect of
ketamine compared with the groups treated with memantine.
Volatile anesthetics and nitrous oxide are suppressive to myo-
genic motor-evoked responses,3 but ketamine is recommend-
ed as a suitable supplement to opioid/nitrous oxide anesthe-
sia in men.4 In our experiments we used ketamine to keep the
experimental conditions constant and to avoid false positive
depression of motor-evoked potentials due to the influence of
an anesthetic.
In regard to the different applications of memantine, we
assumed that intra-arterial infusion of memantine into the
clamped aortic segment would result in better protection than
administering the drug systematically. We were surprised by
the fact that the systemic group did better than the intra-aor-
tic group. We concur that this phenomenon was due to the
slow crossing of memantine through the blood-brain barrier.
Marek Ehrlich, MD
Department of Cardiothoracic Surgery
Mount Sinai Medical Center
One Gustave Levy Place
Box 1028
New York City, NY 10029
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Possible mechanism of calcification of the BioCor
stentless mitral valve treated with the No-React
formula
To the Editor:
I read with great interest the brief communication by Milo
and associates regarding the possible mechanism of calcifica-
tion of the BioCor stentless mitral valve (BioCor,
Belohorizonte, Brazil) treated with the No-React anticalcifi-
cation formula (Shelhigh Inc, Millburn, NJ) in 2 adolescents. 
These 2 children were 13 years old at time of implantation.
Both had mitral and aortic endocarditis. Both needed double
valve replacement. I assume anticoagulation was not an
option. Milo and associates elected to implant the BioCor
stentless aortic and mitral valves treated with No-React anti-
calcification formula in both children. The BioCor mitral
valve was a newly designed porcine mitral valve specially fit-
ted to be implanted in the mitral position. Milo and col-
leagues can be congratulated for the proficient implantations
of the double valves in both children. 
Mechanism of calcification. Once a valve is inflamed or
infected, calcification will occur in a few months or a few
years. Furthermore, nonmoving cusps tend to calcify early.
The BioCor stentless mitral valve is still an experimental
valve design (Fig 1). The major drawback is the length limi-
tations of the chordae. If the patient has a large heart, the
chordae will be too short. This mismatch of chordal length
can cause extra tension and rupture of the chordae. Further-
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